8-K: Mesa Labs Reports Mixed Q1 FY26 Results

Mesa Laboratories reported a 2.4% revenue increase in Q1 FY26, but operating income declined significantly due to FX and non-cash stock-based compensation, alongside challenges in China and BPD segment delays.

Summary

• Total revenues increased 2.4% to $59,543 for the first fiscal quarter ended June 30, 2025, compared to $58,170 in the prior year quarter.
• Non-GAAP core organic revenues growth was 0.4%.
• Operating income decreased 45.1% to $3,064, primarily due to impacts of foreign exchange (FX) and non-cash stock-based compensation expense.
• Non-GAAP adjusted operating income (AOI) excluding unusual items decreased 15.9% to $12,902, representing 21.7% of revenues, down from 26.4% in the same quarter prior year and 23.5% for FY25.
• Net income increased 40.0% to $4,742, or $0.85 per diluted share.
• Gross profit percentage contracted by 200 basis points compared to the first quarter of the prior year, with 40 bps associated with tariff-related charges.
• Operating expenses increased 250 basis points versus the same quarter prior year due to investments in commercial resources and significant FX impact.
• The Total Net Leverage Ratio was 3.16 as of June 30, 2025.
• Biopharmaceutical Development (BPD) segment experienced approximately $1.5 million of expected 1Q26 revenues shifting into 2Q26 due to tariff surcharges.
• Clinical Genomics (CG) China revenues contracted by approximately $1.8 million, or 69%, compared to the same quarter in the prior year.

Sentiment

Score: 4

Explanation: While total revenues and net income increased, core organic growth was minimal, and key profitability metrics (operating income, AOI, gross profit percentage) significantly declined. Challenges in China and BPD segment delays impacted performance, though management expects improvement in Q2.

Positives

• Total revenues increased 2.4% to $59,543.
• Net income increased 40.0% to $4,742, and diluted earnings per share rose to $0.85 from $0.62.
• The Sterilization and Disinfection Control (SDC) division delivered strong core organic revenues growth of 7.5%, driven by commercial execution and a reduction in past-due backlog.
• SDC's gross profit percentage increased by 370 basis points, partly due to a non-cash inventory step-up benefit in the prior year.
• The Calibration Solutions (CS) division achieved 4.8% core organic revenues growth, primarily from strong commercial execution in renal care and price increases.
• Clinical Genomics (CG) growth outside of China was 7.9%, primarily from consumables.
• Management expects to meet revenue goals for the first half of the fiscal year.
• Management anticipates AOI excluding unusual items as a percentage of revenues to meaningfully improve in the second quarter.
• Ongoing internal process improvements through 'The Mesa Way' operating model are expected to drive sustained material improvements.

Negatives

• Non-GAAP core organic revenues growth was a modest 0.4%.
• Operating income decreased significantly by 45.1% to $3,064.
• Non-GAAP adjusted operating income (AOI) excluding unusual items decreased 15.9% to $12,902.
• AOI as a percentage of revenues contracted to 21.7% from 26.4% in the prior year quarter and 23.5% for FY25.
• Overall gross profit percentage contracted by 200 basis points.
• Operating expenses increased 250 basis points due to investments in commercial resources and significant FX impact.
• The Biopharmaceutical Development (BPD) division experienced a 7.0% core organic revenues decline due to timing of order placements and shipping delays.
• BPD's gross profit percentage contracted by 1,140 basis points due to unfavorable product mix, delayed volumes, and FX (SEK appreciation).
• The Clinical Genomics (CG) division saw a 10.7% core organic revenues decline, primarily due to a 69% ($1.8 million) contraction in China revenues.
• CG China contraction was driven by macroeconomic and tariff uncertainty, as well as ongoing regulatory headwinds.
• Calibration Solutions (CS) gross profit percentage decreased by 440 basis points due to raw material price headwinds (tariffs), increased labor costs, and product mix.
• Approximately 1% of revenues were paid in tariffs, impacting the bottom line.

Risks

• Ability to successfully grow the business, including as a result of acquisitions.
• Ability to consummate acquisitions at historical rates and appropriate prices.
• Ability to effectively integrate acquired businesses and achieve desired results.
• Market acceptance of products and reduced demand for products that adversely impacts future revenues, cash flows, results of operations, and financial condition.
• Conditions in the global economy and the particular markets served.
• Significant developments or uncertainties stemming from actions of the U.S. government, including changes in U.S. trade policies and medical device regulations.
• Timely development and commercialization, and customer acceptance, of enhanced and new products and services.
• Inherent uncertainty of projections of revenues, growth, operating results, profit margins, expenses, earnings, margins, tax rates, tax provisions, cash flows, liquidity, demand, and competition.
• Effects of additional actions taken to become more efficient or reduce costs, including restructuring activities.
• Laws regulating fraud and abuse in the health care industry and the privacy and security of health and personal information.
• Outstanding claims, legal proceedings, tax audits and assessments, and other contingent liabilities.
• Foreign currency exchange rates and fluctuations in those rates.
• General economic, industry, and capital markets conditions.

Future Outlook

Management expects to meet revenue goals for the first half of the fiscal year. They anticipate that adjusted operating income (AOI) excluding unusual items as a percentage of revenues will meaningfully improve in the second quarter. The company also expects to continue reducing its past due backlog over the remainder of fiscal year 2026. For the full fiscal year 2026, the Biopharmaceutical Development (BPD) segment's product mix is expected to normalize, leading to an improvement in gross profit percentage. The new product development and commercial strategy in Clinical Genomics (CG) is expected to continue delivering results over the remainder of the fiscal year, and sustained material improvements are expected from the 'Breakthrough 7' initiatives.

Management Comments

• "Against a highly volatile macroeconomic environment, the teams leverage of the Mesa Way operating model delivered quarterly revenues of $59,543 or 2.4% organic (0.4% core organic) revenues growth."
• "Negotiating final tariff surcharges in BPD resulted in approximately $1.5M of expected 1Q26 revenues shifting into 2Q26."
• "Strong growth in SDC and CG growth of 7.9% excluding China overcame a continued contraction of CG China revenues of approximately $1.8M or 69% as compared to the same quarter in the prior year."
• "In consideration of BPD timing delays and overall bookings strength, we expect to meet our revenue goals for the first half of the fiscal year."
• "Profitability for the quarter, using our preferred metric of AOI excluding unusual items as a percentage of revenues, was 21.7% as compared to 26.4% in the same quarter of the prior year and 23.5% for FY25."
• "In total we paid approximately 1% of revenues in tariffs with a significant portion either passed onto customers or capitalized into inventory."
• "With the expected additional revenue in 2Q26, we expect to see AOI excluding unusual items as a percentage of revenues to meaningfully improve in the second quarter."
• "Continuously improving our internal processes is the best way to counter macroeconomic storms. The Mesa Way was in action this May in Breakthrough 7, where we began deploying this years Clinical Genomics divisions strategic plan."
• "While 1Q26 was challenging in the face of a difficult macroeconomic environment, we are encouraged by our continuing commercial success, traction with key initiatives, and the resilience of our operating model."

Industry Context

Mesa Laboratories operates in the life science tools and critical quality control solutions sectors, serving the pharmaceutical, healthcare, and medical device industries. The company's performance is influenced by a highly volatile macroeconomic environment, tariff uncertainty, and ongoing regulatory headwinds, particularly in China, which significantly impacted its Clinical Genomics division. The company is actively working to counter these industry-wide challenges through internal process improvements and strategic pricing adjustments.

Stakeholder Impact

• Shareholders: Experienced mixed results with revenue growth but significant profitability decline, though management projects improvement in the next quarter.
• Customers: May face price increases or surcharges due to the company's efforts to counter tariff impacts, balanced with a focus on customer retention.
• Employees: Investments in commercial resources were made in the prior fiscal year, and internal process improvements are ongoing through 'The Mesa Way' operating model.

Next Steps

• Continue to reduce past due backlog over the remainder of fiscal year 2026.
• Work diligently to counter the impact of tariffs on the bottom line through a combination of price increases or surcharges while prioritizing customer retention and topline growth.
• Sustain material improvements from 'Breakthrough 7' initiatives focused on accelerating New Product Development, excellence in Product Launches, Customer Prospecting, and Manufacturing Scrap Reduction.
• Continue to deliver on new product development and commercial strategy in the Clinical Genomics division over the remainder of the fiscal year.

Key Dates

Recommendation

The company demonstrated resilience with overall revenue growth and a notable increase in net income. Management has identified the challenges (tariffs, China contraction, BPD delays) and outlined clear strategies, including internal process improvements and expected Q2 recovery in profitability. However, the significant decline in operating income and core organic growth, coupled with ongoing macroeconomic headwinds, warrants caution. The stock is not a strong buy given the current profitability pressures, but the strategic initiatives and anticipated near-term improvements suggest holding rather than selling.

Keywords

Mesa Laboratories, MLAB, Q1 2026, Earnings, Financial Results, Life Science Tools, Quality Control, Sterilization, Disinfection Control, Clinical Genomics, Biopharmaceutical Development, Calibration Solutions, SEC Filing, 8-K, Healthcare, Medical Device, NASDAQ